Healthcare

Research and development expenses reached $26.1 million for the quarter, up from a year earlier. For a clinical-stage company, that line is the largest driver of losses, because it covers trial enrollment, manufacturing, drugSupplyand the personnel needed to run studies.

During the third quarter, Atea announced positive topline results from C-BEYOND, a Phase 3 trial in North America. Topline results are the first summary of a trial's primary outcomes, released before the full data set is analyzed and published. Phase 3 trials are the …

Cash, cash equivalents, bank deposits and money market funds were $1.0 million as of June 30, 2026, according to the company's report.

AbCellera reported a net loss of $40.8 million for the quarter ended September 30, 2026. The company's net loss in the prior-year quarter was higher, according to the comparison the company reported. The company develops antibody medicines and uses its discovery platform to identify …

For the year ended 30 June 2026, Trajan (ASX:TRJ) recorded revenue of AUD 161.4 million, a decline of 3.1% year on year. Normalised EBITDA fell 14.7% to AUD 13.2 million. The company also reported operating NPATA of AUD 2.2 million and a pro forma …

Third-quarter 2026 sales were USD 25.399 billion, compared with USD 23.993 billion a year earlier. That represents reported growth of 5.9%, while operational sales increased 6.0%. The company recordedGAAPdiluted earnings of USD 0.09 per share, affected by special charges associated with the proposed talc …

UnitedHealth Group generated USD 112.7 billion in third-quarter revenue during 2026 and reported USD 6.6 billion in earnings from operations. The netMarginwas 3.6%. Diluted earnings were USD 4.56 per share, while adjusted earnings were USD 4.69 per share. The contrast between these measures should …